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Lung cancer is the main cause of cancer-related death worldwide and conventional treatment
strategies must be improved. In addition to mutations in several well-known cancer-associated
genes, recent advances in sequencing technology have led to the discovery of numerous novel
gene mutations and translocations. Some of these genomic aberrations occur at similar
frequencies in all lung cancer subtypes, whereas others appear to be speciﬁc for adenocarci-
noma or squamous cell lung cancer. High frequency mutations or recurrent translocations
support involvement of the affected genes in the pathogenesis of lung cancer. The presence of
activating aberrations is indicative for putative driver genes that might be essential for tumor
cell growth and survival. These driver genes are potential targets for developing new
treatments for lung cancer patients. Indeed, multiple tyrosine kinase inhibitors (TKIs) are
currently used to treat lung cancer patients based on the presence of activating mutations, and
novel drugs are under investigation. Patients beneﬁt for about one year from current targeted
treatments, but progression of disease inevitably occurs and resistance of the tumor to the TKI
used can be observed in re-biopsied tumor samples. The aim of this review is to provide an
overview of mutated genes in non-small cell lung cancer, an overview of targeted treatment
strategies that are currently applied, and the known resistance mechanisms.




in this manuscript.1. Lung cancer
Lung cancer is the leading cause of cancer-related deaths
worldwide, with over 228,000 new cases and more than
159,000 deaths reported in 2013 in the United States [1,2].
A. Saber et al.24Overall, the 5-year survival rate is about 16% and late
diagnosis is signiﬁcantly associated with poor prognosis [1].
Lung cancer can be divided into two main subtypes based on
histology: small cell lung cancer (SCLC) and non-small cell
lung cancer (NSCLC). Approximately 85% of lung cancer
patients are diagnosed with NSCLC [3], which can be further
subdivided into three main groups, i.e. adenocarcinoma
(AC), squamous cell carcinoma (SQCC), and large cell car-
cinoma [4]. The AC subtype used to be more frequent in
women and non-smokers, but nowadays it is more frequent
than other histological subtypes in both men and women
[3]. The diagnosis of lung cancer is made by histology/
cytology of a tumor detected by imaging techniques such as
computed tomography (CT) and positron emission tomogra-
phy (PET) [5]. Treatment of lung cancer patients depends
primarily on the performance status, stage of the disease,
the presence of oligometastases and on histological type
[6]. Surgery is the primary treatment for patients with stage
I or II NSCLC [7], although adjuvant chemotherapy is advised
by many guidelines to increase survival of the patients. In
non-resectable, stage III NSCLC disease, chemoradiation is
the preferred treatment [8]. Nowadays, treatment of lung
cancer patients with advanced disease is guided by muta-
tion analysis in the case of a documented tumor-driver
mutation. The number of different tyrosine kinase inhibitors
(TKIs) available for the treatment of non-small cell lung
cancer patients is rapidly increasing due to new diagnostic
developments.
In this review we give a brief overview of genes mutated
in lung cancer, followed by a more in depth overview on
potential therapeutic targets identiﬁed by next generation
sequencing (NGS) technology. We also provide an overview
of current targeted treatment approaches and the known
resistance mechanisms.2. Mutational landscape of lung cancer
Lung cancer, like other malignant neoplasms, is a result of
an accumulation of different genetic alternations during life
[9]. The TP53 gene, originally described in 1979 [10], was
the ﬁrst tumor suppressor gene to be discovered. TP53 is
mutated in approximately 45% of NSCLC patients [11]. In
1982, a human gene with transforming activity was identi-
ﬁed in a lung carcinoma cell line. This gene is homologous to
the Kirsten Rat Sarcoma virus [12] and was referred to as
KRAS. Mutations in KRAS are mostly found in codons 12, 13,
and 61. They occur more frequently in patients with AC (5–40%)
than in other subtypes of lung cancer, and are associated with
smoking behavior [9].
Developments in sequencing technologies in recent years
and the need to identify novel therapeutic targets have
encouraged scientists to sequence large numbers of lung
cancer samples. Entire gene families like protein kinases
[13,14] or a combination of genes known to be mutated in
lung cancer and other cancer types [15] have been ana-
lyzed. Analysis of 518 protein kinases in 33 primary lung
tumors and cell lines revealed 188 somatic mutations in 141
genes, including genes known to have a role in lung
tumorigenesis. For 21 genes, mutations were found in more
than two samples. Seven of these genes had mutations in
the kinase domain, including BRAF, MAP2K4 and FGFR2. Inaddition, activating mutations were identiﬁed in FGFR1 and
EPHA5 and inactivating mutations in ATM [13]. Analysis of
623 genes in 188 lung AC specimens by Ding et al. (2008)
revealed 26 frequently mutated genes, including well-
known cancer related genes such as TP53, RB1, EGFR and
KRAS [15]. In addition, they also identiﬁed mutations
in oncogenes such as ERBB4 (HER4), ERBB2 (HER2) and
in multiple ephrin receptors (EPHAs). Altogether they
observed a signiﬁcant excess of mutations and copy number
changes in genes involved in the mTOR, MAPK, Wnt, and the
p53 signaling pathways [15]. Mutation analysis of the coding
regions of more than 1500 genes of 134 primary lung tumors
revealed that 18 and 19 genes were mutated at a frequency
signiﬁcantly above the background mutation rate in AC and
SQCC, respectively. Five of these genes including TP53,
KRAS, KEAP1, MUC16, and BAI3 were shared between AC
and SQCC. Differences in the set of mutated genes for
various subtypes suggest that different mechanisms are
involved in tumorigenesis [16]. Targeted sequencing of 145
cancer-related genes in 24 NSCLC biopsy samples, by Lipson
and colleagues in 2012, revealed recurrent mutations in 21
genes, including well-known lung cancer genes together
with mutations in druggable lung cancer genes such as BRAF
and EGFR [17].
Together, these initial targeted and high throughput
approaches indicated several targets, such as EGFR, KRAS,
BRAF and EML4-ALK, that are nowadays treated with
selected targeted drugs in the clinic. Although only a small
proportion of all NSCLC patients (approximately 7%) will
proﬁt from these treatments (patients with complete and
partial response), several tens of thousands of patients can
still beneﬁt worldwide because about 25% of patients with
the subtype histology AC are suitable for studies with
targeted therapies.2.1. Potential therapeutic targets identiﬁed by
next generation sequencing
Whole genome and exome sequencing (WGS and WES,
respectively) have enabled researchers to dig even deeper
into the mutational landscape of different cancer subtypes.
These developments led to increased output of sequencing
studies [18]. NGS gives us the opportunity to generate large
amount of sequencing data within limited time period in a
more cost effective way compared to conventional sequen-
cing. Although, NGS is being improved every day, still we
need to be careful in data interpretation and mutation
calling. For instance, artifacts that can occur during sample
preparation, ampliﬁcation bias and DNA polymerase error
should be always taken into account while working with NGS
data [19].
A comprehensive overview of mutation frequencies per
gene for all types of cancer is given in the COSMIC database
(〈http://cancer.sanger.ac.uk/cancergenome/projects/cos
mic/〉). For lung cancer, the top-20 most commonly mutated
genes are shown in Fig. 1.
The ﬁrst studies on lung cancer using massively parallel
sequencing have been performed on either cell lines or
single primary tumors [20–22]. A complete genomic analysis
of a single NSCLC primary tumor revealed more than 50,000
somatic variations, including new mutations in genes known
Fig. 1 A schematic representation of the top-20 mutated genes in lung cancer overall and in the three main subtypes based on the
COSMIC database (2014). In this database, mutation frequencies were calculated using a weighted average mutation frequency
based on sample size across all studies. See the COSMIC website for more information (〈http://cancer.sanger.ac.uk/cancergenome/
projects/cosmic/〉). Black bars: Nonsense and indel frameshifts; white bars: missense, synonymous, in-frame ins/del, complex and
other mutations. Bold genes: These are among the top-20 genes in at least 2 out of 3 subtypes.
25Genomic aberrations guiding treatment of non-small cell lung cancer patientsto be mutated at a high frequency in lung cancer, such as
NF1 [20]. Mutation analysis using WGS on a lung AC and a liver
metastasis of the same patient resulted in the detection of a
KIF5B-RET fusion gene [23] similar to the previous report [17].
As KIF5B-RET is quite common, it might have an important
functional role in the pathogenesis of lung cancer.
Liu and colleagues [24] performed WES on a cohort of 31
primary non-small cell lung cancer (NSCLC) tumors and
showed somatic mutations in several known lung cancer
genes, including some of the targetable ones such as EGFR
and ERBB2 (HER2). Moreover, mutations were identiﬁed in
DCC and MML3, which are targets for treatment in colon
cancer and leukemia, respectively. CSMD3 mutations were
detected in 19% of the patients; notably, this gene was the
second most frequently mutated gene in their cohort after
TP53.
WGS in a panel of 17 NSCLC primary tumors revealed nine
commonly mutated genes, including several known lung
cancer genes and three novel lung cancer genes such as
DACH1, a tumor suppressor gene in prostate cancer and
gliomas, and two fusion genes: EML4-ALK and KDELR2-ROS1
[25]. They also detected mutations in JAK2 similar to a previousreport using a targeted approach [17]. JAK2 inhibitors are used
to treat patients with myeloﬁbrosis [26].
One of the largest studies to date performed WES on
178 lung SQCC samples and identiﬁed over 48,000 non-
silent mutations [27]. As expected, TP53 was the most
commonly mutated gene with a frequency of 81%. Inacti-
vating mutations in CDKN2A, KEAP1, CUL3, NOTCH1 and
NOTCH2 were identiﬁed, as well as activating mutations
in and ampliﬁcation of NFE2L2, a key component of the
oxidative stress response pathway [27]. Activation of the
NFE2L2-KEAP1 signaling pathway through mutations in
NFE2L2 is a characteristic of pediatric liver tumors as
well [28]. The Cancer Genome Atlas (TCGA) Network also
found SOX2 and TP63 to be activated via ampliﬁcation.
These two genes are important components of the squa-
mous cell differentiation pathway. They identiﬁed three
tyrosine kinase families which are potentially targetable,
including ERBB, FGFR and JAK, all of which were mutated
and/or ampliﬁed [27].
In a study [29] of 183 lung AC samples, 25 genes were
signiﬁcantly mutated, of which 19 had been reported
previously and six were novel genes in lung AC, including
A. Saber et al.26CHEK2 and BRD3. In this study the authors also found
inactivating mutations in STK11, PTEN, RB1, SETD2 and
CDKN2A [29] and CTNNB1 was found to be mutated in 3% of
the patients. This gene is highly mutated (70%) in liver
cancer patients and it is a component of WNT-CTNNB1
pathway [28,29].
A study [30] on a large cohort of Korean patients (n=104)
with SQCC showed a good overlap with sequencing data
previously published by TCGA Network [27], but also
reported some marked differences. CDKN2A mutations were
less common in Korean patients, while mutations in RB1
were signiﬁcantly more frequent. Interestingly, they found
activating mutations in PIK3CA, which is one of the ther-
apeutic targets of the PI3K/AKT/mTOR pathway. In one of
the Korean lung cancer samples, an FGFR3-TACC3 fusion
transcript was detected [30]. FGFR3 has been reported as a
potential therapeutic target in glioblastoma and bladder
cancer [31,32].
Together, these next generation studies have made sig-
niﬁcant contributions to the identiﬁcation of genes that are
of interest as novel targets for therapy. To select the most
promising target, it is essential to reveal the impact of the
mutations and to discriminate between activating driver
mutations and non-driver or inactivating mutations. In
summary, next generation and targeted sequencing indicate
that genes such as ERBB2 (HER2), ERBB4, JAK2, RET, ROS1,
DCC, MLL3 might be good candidates for targeted treatment
in lung cancer patients. In addition, inhibitors of the MEK
kinase could be tested in tumors with NF1 mutations. More
importantly, PIK3CA seems to be a suitable candidate,
together with FGFR3 and NFE2L2, for treatment of patients
with SQCC. At the moment, inhibitors for RET and ROS1
fusions are in preclinical and clinical trials and ROS1
inhibitors might also be effective on patients with activating
ROS1 mutations.
3. Targeted therapies currently in use
Speciﬁc aberrations in genes or pathways can lead to increased
protein levels, and/or pre-active protein kinases that stimulate
tumor cell growth. These aberrations can be targeted with
small molecules such as TKIs (administered orally) and/or with
monoclonal antibodies that are administered intravenously. At
the moment, more clinical targets have been discovered in AC
than in SQCC. Commonly used therapies in AC target the
tyrosine kinase part of EGFR, HER2, VEGFR and ALK protein
[33]. In addition, a number of novel drugs against KRAS (AC/
SQCC), BRAF (AC/SQCC), ROS1 (AC), RET (AC), FGFR1 (SQCC),
PIK3CA (AC/SQCC) and DDR2 (SQCC) are being evaluated in
clinical trials or soon will be [34]. The known target genes,
the kinase inhibitors used, and clinical outcomes in non-SQCC
clinical trials phase III are summarized in Table 1. No phase III
study has been performed in SQCC yet. Therefore, we only
focus on non-SQCC. Frequencies of hotspot mutations, fusion
genes and possible resistance mechanisms are summarized in
Tables 2 and 3.
3.1. EGFR inhibitors
TKIs, such as erlotinib, geﬁtinib, and afatinib, are currently
registered for treatment of EGFR mutant non-SQCCpatients. Patients with activating EGFR mutations, such as
exon 19 insertions/deletions, and nonsynonymous mutations
such as G719X in exon 18, or L858R and L861Q in exon 21,
are sensitive to erlotinib and geﬁtinib, with a tumor
response of about 75%. Patients with such mutations show
an increased progression-free survival (PFS) after targeted
treatment compared to treatment with chemotherapy [35].
This effect was observed in both ﬁrst and second line
treatment. Hazard ratios for progression-free survival var-
ied between 0.43 and 0.34. Most pivotal studies of ﬁrst-line
EGFR-TKI were limited to lung cancer patients carrying
EGFR exon 19 deletions or L858R point mutations. Only
patients with EGFR exon 19 deletions showed an overall
survival beneﬁt with afatinib.
The effect of EGFR-TKI in patients with rare EGFR muta-
tions has not been deﬁned but seems less striking [36].
A meta-analysis revealed a signiﬁcant association between
increased EGFR copy number and improved survival outcome
[37]. In NSCLC, EGFR mutation screening is the best method
to predict tumor response to TKIs compared to ﬂuorescence
in situ hybridization (FISH) and immunohistochemistry [38].
In almost 25% of patients tumor growth is enhanced when
EGFR treatment is ended, indicating that the tumor remains
at least partly dependent on the EGFR signaling [39].
3.2. Mechanisms of resistance to EGFR inhibitors
After 9 to 12 months of treatment with an EGFR-TKI, the
tumor appears to become resistant due to a spectrum of
mechanisms. In about 50% of cases, an originally low-
frequency TKI-resistant mutation, the T790M (gatekeeper)
mutation, can increase to detectable and clinically relevant
frequencies upon treatment with a TKI. In addition, ampli-
ﬁcation of MET or HER2, mutations in PKI3CA or BRAF,
activation of the AXL kinase, and transformation to small
cell lung cancer are the most prominently induced resis-
tance mechanisms to TKI treatment [34,40]. These last two
mechanisms have been proven in cell lines, xenografts or
tumors of patients, and can therefore be considered as truly
causative in relation to the resistance [41–43]. Some authors
proposed that new mutations developing in EGFR (like the
T790M gatekeeper mutation) are associated with resistance
in patients treated with EGFR-TKI [40], but also mutations
in other genes such as GAS6, VIM, NF-kB, ADAM17 and
NOTCH1 have been found in tumors of patients who became
resistant to EGFR-TKI [43–45]. Finally, in studies using cell
lines, mutations in COL6A1, IGFR1, TGFB or mTOR genes or
mutations affecting the Hedgehog, pp.53, Wnt pathways
were found to be associated with resistance mechanisms
[43]. A true causal relation needs to be proven for these
mechanisms.
3.3. BRAF inhibitors
BRAF is a serine/threonine kinase that is activated by RAS
and signals its proliferative actions through MEK kinase. BRAF
mutations are more common in lung ACs but are observed in
less than 1% of NSCLC tumors [46]. In a study of 697 lung AC
patients, BRAF mutations were present in 18 patients (3%),
half were V600E (50%), the other most common mutations
were G469A (39%) and D594G (11%) [47]. NSCLC patients with
Table 1 Overview of targeted phase III studies in advanced non-SQCC.
Protein/Inhibitors Mutation % in non-SQCC subtype Study Progression-free survival hazard ratio (95% CI)
EGFR 10%
erlotinib EURTAC 0.37 (0.25–0.54)
OPTIMAL 0.16 (0.11–0.26)
geﬁtinib IPASS 0.48 (0.36–0.64)
WJOTG3405 0.52 (0.38–0.72)
NEJ002 0.32 (0.24–0.44)
afatinib LuxLung 3 0.58 (0.43–0.78)















No phase III study in SQCC is available. N/A: Not available
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and overall survival after chemotherapy than patients with-
out such mutations. At the moment, vemuraﬁnib and dabra-
fenib are the two BRAF inhibitors that are clinically available.
There are two case reports of lung AC patients with a V600E
mutation who responded to treatment with vemuraﬁnib
[48,49]. The ﬁrst, still ongoing, experience with dabrafenib
in advanced NSCLC showed a tumor response rate of 40% [50].
Preclinical data suggest that non-V600E-mutated BRAF kinases
are resistant to vemurafenib. In addition, BRAF mutations may
predict sensitivity of NSCLC cells to MEK inhibitors [51].3.4. Mechanisms of resistance to BRAF inhibitors
Different resistance mechanisms have been found in preclinical
studies. A switch of full-length BRAF to aberrant BRAF (p61VE)
has been shown in treated cell lines becoming resistant to
BRAF inhibitors. Another mechanism that has been described in
cell lines is upregulation of the EGFR protein due to loss of the
c-Jun feedback loop [52]. A single lung cancer patient with a
BRAF mutation and treated with dabrafenib showed a KRAS
mutation in a re-biopsy at tumor progression. The hypothesis
was therefore put forward that the cause of resistance was due
to a G12D KRAS mutation [53]. Other mechanisms that have
been described mostly in melanoma are MAPK-dependent
mechanisms, like NRAS or CRAF upregulation, BRAF upregula-
tion and MEK mutations. MAPK-independent mechanisms, like
PTEN loss and upregulation of PDGFR-β and IGF-1 R, have also
been described [54].3.5. ALK inhibitors
EML4-ALK is a fusion gene generated by an inversion of a
segment of chromosome 2. It was the ﬁrst targetable fusion
onco-kinase identiﬁed in NSCLC [34]. It is most often
observed in young, light- or never smoking patients, occur-
ring equally in males and females [55]. It can be detected in
up to 4% of NSCLC patients [34] and 3–6% of patients with
lung AC [56]. ALK fusion genes rarely coexist with KRAS or
EGFR mutations in lung cancer patients [57]. The EML4-ALK
fusion protein results in enhanced ALK kinase activity [55].
Crizotinib was the ﬁrst registered ALK inhibitor used in
clinical practice (Table 1). It was originally designed for
inhibition of the c-MET protein but it turned out to have an
inhibitory effect on ALK kinase as well [58]. The overall
response rate in a FISH-based ALK-positive NSCLC group treated
with crizotinib was 65% (95% conﬁdence interval [CI]; 58–72)
versus 20% (95% CI; 14–26) in the chemotherapy group. In a
phase III study, the median PFS for crizotinib was 7.7 months.
In the chemotherapy group PFS was 3.0 months [59].
Ceritinib and alectinib are also two potent second gen-
eration ALK-TKIs [60] that can be used in crizotinib resistant
patients [61,62]. In a phase I clinical trial, Shaw and colleagues
treated ALK-positive patients with ceritinib. Majority of the
patients had been pretreated with crizotinib. The overall
response rate with ceritinib was 58% (95% CI; 48–67), median
PFS was 7 months in those who received 4400 mg daily.
Moreover, they observed tumor responses in patients with
different ALK resistance mutations (L1196M, G1269A and
S1206Y) as well as the patients without any detectable ALK
mutation [61]. Treatment of an AC patient with alectinib
Table 2 Frequencies of mutation and fusion partners of
























BRAF V600E 50% [47]
G469A 39%
D594G 11%













Table 3 Proposed resistance mechanisms in targetable
mutations and translocations in non-SQCC.
Protein Resistance mechanisms References
EGFR AXL/GAS6 axis activation [43]







Mutations in COL6A1/ IGFR1/
Hedgehog/ TGFB/ p53/ Wnt/mTOR
pathways
[40,43]






ALK ALK mutation [15,63–64]





ROS1 ROS1 mutations [73,75]
Signaling switch to EGFR [74]
KRAS/NRAS mutations [76]
KRAS overexpression [76]
A. Saber et al.28(300 mg twice daily) resulted in complete response [62]. Both
drugs are also effective for brain metastasis.
3.6. Mechanisms of resistance to ALK inhibitors
ALK-positive patients develop tumor resistance to targeted
therapy. This resistance can be due to gatekeeper mutations
in the kinase domain of the ALK gene (L1196M and G1269A),
copy number gain of the EML4-ALK fusion gene, and muta-
tions in EGFR and KRAS [63]. Other reported ALK mutations
linked to resistance are V1135E, L1152R, C1156Y, F1174L,
L1198P, G1202R, D1203N, S1206Y, G1269S, G1269A and
L1318M. Targeted NGS showed an association between the
development of resistance to crizotinib in two patients and new
nonsynonymous mutations outside the ALK kinase domain
[15,63–65]. The observation of different nonsynonymous muta-
tions in MET could be important because crizotinib also is a
potent MET inhibitor [66]. And lastly, mutations in pathways of
AXL and the development of epithelial-mesenchymal transition
(EMT) have been described as factors that contribute to ALK-TKI
resistance [67].3.7. ROS1 inhibitors
In about 1–2% of patients with NSCLC, a translocation of ROS1,
which is located on chromosomal region 6q22, has been found
with different fusion partners (SLC34A2, SDC4, CD74, EZR).
Preclinical studies and case reports show that ROS1 kinase
activity is inhibited by crizotinib. ROS1 fusions occur more
often in younger patients and in the AC subtype [68,69].
Crizotinib is a potent inhibitor of cell growth in cell lines as
well as in patients with a ROS1 fusion [70]. A phase I clinical
trial by Shaw and colleagues on ﬁfty ROS1-positive patients
with AC subtype treated with crizotinib showed an overall
response rate of 72% (95% CI; 58–84) and the median PFS of
19.2 months [71]. Another study with thirty two AC patients
with ROS rearrangement treated with crizotinib showed an
overall response rate of 80% and median PFS was 9.1 months
[72]. No randomized studies have been published yet.3.8. Mechanisms of resistance to ROS1 inhibitors
A G2032R mutation of ROS1 was found in a crizotinib-
resistant patient. Foretinib (a MET and VEGFR inhibitor)
seems to be a potent compound to overcome this resistance
[73]. In the search for resistance mechanisms in cell lines,
a switch in signaling from ROS1 to EGFR was observed,
when ROS1 was inhibited by crizotinib [74]. The same study
29Genomic aberrations guiding treatment of non-small cell lung cancer patientsalso reported that treatment with an EGFR inhibitor in
combination with a ROS1 inhibitor was effective in cell lines
resistant to ROS1 inhibitors. In another study, a new mutation,
L2155S, was found in a ROS1-positive NSCLC cell line resistant
to crizotinib. Authors also showed that L2155S and G2032R
mutations can induce resistance to crizotinib in Ba/F3 cells
[75]. KRAS/NRAS mutations or KRAS overexpression have been
shown as other possible resistance mechanisms to crizotinib in
HCC78-crizotinib resistant cell line [76].
3.9. RET inhibitors
A translocation of the rearranged during transfection (RET)
gene located at chromosome 10 can be identiﬁed in about
1% of non-smoking patients with lung ACs. KIF5B, CCDC6,
TRIM33 and NCOA4 serve as fusion partners [77,78]. As a
result of this fusion, the normally low expression level of
RET is increased in lung AC cells [79]. Over 12 drugs have
been described wit RET inhibitory properties [80]. Most
potent were cabozantinib (IC50 4 nM), alectinib (IC50 4.8 nM)
and ponatinib (IC50 7 nM) [80,81]. Vandetanib, sunitinib,
sorafenib and cabozantinib are all multikinase inhibitors,
and the ﬁrst three show in vitro activity against RET
expressing NIH3T3 and Ba/F3 cell lines [17]. It has been
shown that alectinib can inhibit cell growth by suppressing
phosphorylated RET both in cell line and RET-positive mouse
model [81]. A case report conﬁrmed the anti-tumor effects of
vandetanib in a NSCLC patient [82]. In a phase II clinical trial,
cabozantinib was tested on three RET-positive patients. Two of
the patients showed partial response, while the other one
remained with stable disease [78].
3.10. HER2 and cMET
HER2 is mutated (mostly exon 20) in approximately 2% of
NSCLC patients [83]. Activating mutations in HER2 will
result in activation of downstream signaling pathways
(AKT and MEK) leading to cell proliferation and survival
[84]. Blocking HER2 in HER2-mutated cell line resulted in
cell cycle arrest and cell death [85]. Treatment of sixteen
NSCLC patients with different combination of HER2 inhibi-
tors (showed a median PFS of 5.1 months [83].
cMET is a tyrosine kinase receptor (TKR) which is coded
by MET proto-oncogene and it is widely expressed by cells
with epithelial-endothelial origin [86]. Different mechan-
isms can lead to aberrant activation of MET such as MET
gene mutation or ampliﬁcation and cMET/HGF overxpres-
sion [87]. Preclinical studies revealed inhibition of cell
growth by crizotinib in MET dependent lung cancer cell lines,
while tivantinib is independent of MET signaling and results is
apoptosis [88]. A phase I clinical trial showed that tivantinib in
combination with erlotinib was well tolerated in advanced
NSCLC patients based on CYP2C19 genotype [89]. A phase II
study showed a median PFS of 3.8 months in erlotinib plus
tivantinib group compared to erlotinib or tivantinib plus placebo
group [90]. Several clinical trials are still ongoing.
4. Conclusion
Nowadays, more and more somatic mutations and fusion genes
are being identiﬁed using NGS approaches. The affected genescan be considered as potential targets for treatment of NSCLC.
At the moment, we only have a few gene mutations and fusion
genes that can be targeted with TKIs, although many other
speciﬁc TKIs are under investigation. A striking and common
feature is that tumor resistance develops after about one year
of targeted treatment. Therefore, the search for different
resistance mechanisms is important so that treatment regimens
can be adapted at an early enough stage. At the moment, most
resistance mechanisms are described on the basis of their
associations with newly detected mutations observed at disease
progression. We need to put more effort into functional studies
to discover the role of mutations in new and known cancer
genes and to deﬁne novel therapeutic drivers, which may even
be genes with mutations at low frequencies. This is important,
because even a gene with a low mutation frequency can save a
considerable number of patients with NSCLC.
In the future, we need to integrate the NGS results with
epigenetic, transcriptome, copy number and proteomic
analyses. This should preferably be done in primary tumors,
metastases and the subsequent relapses with developing
resistance to gain a good insight into the tumor cell evolution
and to help design strategies to treat lung cancer patients
optimally. Moreover, complete overviews of the mutational
landscape of each patient's tumor will aid providing persona-
lized therapy to patients and allow a timely switch to drugs
that attack or work round resistance.
Combination therapies of different targeting drugs that
are based on this mutational landscape will probably be
more effective in prolonging the survival of patients and
increasing their quality of live. Nowadays, the treatment of
cancer patients should be based more on their genetic
proﬁles and less on traditional organ- or cancer subtype-
based strategies.
Three kinds of lung cancer patient groups may emerge in
the future. In the ﬁrst group are younger patients – mainly
past, light or non-smokers – with limited somatic genomic
instabilities that have one or two driver genomic aberration
(s) that can be targeted with small molecules or combina-
tions of these drugs. In the second group, smoking patients
with SQCC usually have many somatic genomic alterations.
These genomic changes might result in many abnormal
peptides or proteins that can be recognized by the immune
system and may induce an immune response. These patients
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